Industrial Technology Research Institute

Kuo-Kuei Huang

Meng-Nan Lin

I-Horng Pan

Jir-Mehng Lo

Pei-Hsin Lin

Ying-Fei Tsai

Jennline Sheu

Lain-Tze Lee

Chu-Hsun Lu

Yi-Ching Lee

Cheng-Yu Lee

Shu-Fang Wen

Chih-Peng Liu

Yi-Cheng Cheng

Ying-Chu Shih

Zong-Keng Kuo

Tien-Soung Tong

I-Huang Lu

Jui-Hung Yen

Pei-Ru Liau

Chih-Hung Chen

I-Hong Pan

Chrong-Shiong Hwang

Tsan-Lin Hu

Shu-Jiau Chiou

Maggie Lu

Yi-Hsun Chen

Jenn-Line Sheu

Felice Cheng

Chia-Ching Chen

Shao-Chan Yin

Hui-Ju Liang

Jui-Wen Huang

Tze-Chung Lee

Bie-Shung Tsai

Ya-Yan Yang

Jia-Horng Liaw

Yen-Jen Wang

Wen-Chia Huang

Chien-Lin Pan

Tze- Chung Lee

A method of treating or alleviating autoimmune-related diseases is provided. The method includes administering a pharmaceutical composition to a subject in need thereof. Moreover, the pharmaceutical composition includes an extract of-as an effective ingredient and a pharmaceutically acceptable carrier or salt.

Method for treating or alleviating autoimmune-related diseases

A composition for improving the solubility of poorly soluble substances is provided. The composition includes about 40-99.5% by weight of cyclodextrin and/or derivatives thereof; about 0.05-10% by weight of at least one water-soluble polymer; and about 0.05-60% by weight of at least one water-soluble stabilizer.

Composition for improving the solubility of poorly soluble substances, use thereof and complex formulation containing thereof

A method of treating or alleviating autoimmune-related diseases is provided. The method comprises administering a pharmaceutical composition to a subject in need thereof. Moreover, the pharmaceutical composition comprises an extract of Amomum tsao-ko as an effective ingredient and a pharmaceutically acceptable carrier or salt.

A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: whereinis a single or double bond, X is NCHor CH, Y is null, O or N, Z is O or N, Ris H, OH, and Ris null, H, C-Calkyl, &#x2014;(C&#x2550;O)-alkyl, &#x2014;(C&#x2550;O)-aryl, &#x2014;(C&#x2550;O)-alkyl-aryl, &#x2014;(C&#x2550;O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of &#x2014;OH, &#x2014;NO, &#x2014;NH, &#x2014;NRR, carbonyl, alkoxyl, alkyl or &#x2014;OCF, wherein Rand Rindependently are H, alkyl, &#x2014;SOCH, &#x2014;(C&#x2550;O)&#x2014;CHor &#x2014;(C&#x2550;O)&#x2014;NH.

Method for treating an autoimmune neurological disease and/or neurodegenerative disease and pharmaceutical formulations for a liquid dosage form and a controlled release dosage form

The present disclosure provides a pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis, including: an effective amount of an extract of a plant belonging toas an effective ingredient for treating or alleviating the autoimmune disease and/or complication thereof and/or nephritis, wherein the autoimmune disease is selected from a group consisting of lupus erythematosus, psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis, Crohn's disease and ulcerative colitis (UC).

Pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis and method for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis

A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided. In formula (I), Ar is indazole, 5-isoquinoline, 6-isoquinoline, or their N-oxide. X is &#x2014;C(&#x2550;Z)&#x2014;, wherein Z is N&#x2014;CN, NH, NR, NCOR, NCONRR, NCO-aryl, S, or O. Y and J are independently H, alkyl, aryl, aminoalkyl, &#x2014;NH, &#x2014;CN, &#x2014;OH, &#x2014;O-alkyl, &#x2014;O-aryl, &#x2014;COOH, &#x2014;COOR, &#x2014;CONHR, &#x2014;CONHCH-aryl, &#x2014;CONRCH-aryl, &#x2014;NHCOR, halogen, halogened alkyl, -alkyl-OR, -alkyl-ONO, alkyl-ONO, &#x2014;OCOOR, &#x2014;O(C&#x2550;O)-aryl, &#x2014;CHROH, &#x2014;CHOH, &#x2014;CHO(C&#x2550;O)-aryl, &#x2014;CHO(C&#x2550;O)&#x2014;R, &#x2014;CHRO(C&#x2550;O)-aryl, &#x2014;CHRO(C&#x2550;O)&#x2014;R, unsaturated carboxylic ester, substituted alkynyl, &#x2014;NHSOR, &#x2014;SOR, &#x2014;SONHR, or &#x2014;SONRR, or Y and J bond together to form a carbocylic or aromatic ring, wherein Rand Rare independently H, substituted C1-C6 alkyl, substituted aryl, cycloalkyl, alkylaryl, -alkyl-NRR, &#x2014;S(O)-(alkyl-NRR). R, Rand Rare H, C1-C6 alkyl, cycloalkyl, aryl, alkylaryl, alkylheteroaryl, alkylheterocycle, wherein any one thereof is optionally substituted with one or more of OH, NO, or NRR. 

Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same

An extract ofsp. in use of arthritis treatment is provided. The extract ofsp. and an active ingredient contained therein, antofine, are applicable to a method, pharmaceutical composition and dietary supplement for treatment of arthritis. A mass production of antofine from plant extracts is also provided.

[object Object]

A pharmaceutical composition with an immunomodulating function is provided, including an extract ofobtained by grinding the, adding the groundto a solvent and isolating the extract from the solvent, wherein thecomprisesand Bupleurums with at least one of the nucleotide sequences selected from a group consisting of SEQ ID NOs. 1&#x2dc;6 and a nucleotide sequence with no more than 1% of the nucleotide sequence divergences of SEQ ID NOs. 1&#x2dc;6, or combinations thereof.

Pharmaceutical composition with immunomodulating function

Growing community of inventors

Zhubei, Taiwan

Kuo-Kuei Huang